

Haematologica
HAEMATOL/2016/161968
Version 3

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

Douglas B. Cines, Jeffrey Wasser, Francesco Rodeghiero, Beng H. Chong, Michael Steurer, Drew Provan, Roger Lyons, Jaime Garcia-Chavez, Nancy Carpenter, Xuena Wang, and Melissa Eisen

Disclosures: This research, including both the original studies and the pooled analysis, was funded by Amgen Inc. Cines: advisory board (Amgen), data safety monitoring board (GSK, Rigel), consultant (Bayer, Novartis, Momenta, Astellas, Ionis, Juno), research support (T2 Biosystems, Syntimmune). Wasser: research support (Amgen, Merck, Incyte, Pfizer), consultant (Amgen, Novartis). Rodeghiero: advisory board (Amgen, GSK/Novartis, LFB, MedImmune, Argenx, UCB). Chong: research support (GSK, Rigel, Incyte, Amgen), consultant (Novartis). Steurer: research support (Amgen, GSK), honoraria (Amgen, GSK). Provan: research support (Amgen, GSK), honoraria (Amgen, GSK), consultant (UCB, MedImmune, Vifor). Lyons: research support (Amgen), consultant (Amgen). Garcia Chavez: research support (Amgen), consultant (Amgen, Novartis). Carpenter, Wang, Eisen: employees and stockholders (Amgen).

Contributions: All authors contributed to data acquisition, either by being an investigator of a study site or by generating the analyses. All authors reviewed the manuscript and approved the final version for submission. Jonathan Latham of PharmaScribe, LLC (on behalf of Amgen Inc.) and Susanna Mac of Amgen Inc. wrote the first draft of the manuscript in close collaboration with DBC, based on an oral presentation at the 2016 EHA annual meeting that was approved by all authors, and provided medical writing assistance throughout.